LB

LB PHARMACEUTICALS INC

Clinical-stage biopharma developing oral therapies for neuropsychiatric diseases like schizophrenia.

LBRX | US

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
575 MADISON AVENUE, 10022 NEW YORK
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

LB Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for neuropsychiatric diseases. The company's pipeline is centered on its lead product candidate, LB-102, an oral small molecule aimed at treating schizophrenia, bipolar depression, and other central nervous system (CNS) disorders. LB Pharmaceuticals is focused on leveraging the therapeutic potential of LB-102, which it believes could become the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all LB PHARMACEUTICALS INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for LB PHARMACEUTICALS INC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for LB PHARMACEUTICALS INC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Kodiak Sciences Inc. Logo
Developing durable biologics to treat high-prevalence retinal diseases and prevent blindness.
United States of America KOD
Kohjin Bio Co., Ltd. Logo
A CDMO providing culture media & bioservices for cell therapy, research, and diagnostics.
Japan 177A
KOLON LIFE SCIENCE Inc. Logo
Develops gene therapies and manufactures APIs, providing global CDMO/CMO services.
South Korea 102940
Kolon TissueGene, Inc. Logo
Developing cell and gene therapies for orthopedic and degenerative disorders.
United States of America 950160
Develops animal health products and novel drugs for human cancer and autoimmune diseases.
South Korea 041960
KOREA ARLICO PHARM CO.,LTD. Logo
Manufactures generic drugs and provides CDMO services to a global market.
South Korea 260660
Develops and manufactures prescription (ETC) and over-the-counter (OTC) medicines for public health.
South Korea 014570
Korro Bio, Inc. Logo
A clinical-stage biopharma using RNA editing to develop medicines for rare & prevalent diseases.
United States of America KRRO
K Pharma,Inc. Logo
Develops iPS cell-based drugs and regenerative medicine for central nervous system disorders.
Japan 4896
Kringle Pharma,Inc. Logo
Develops regenerative HGF medicines for rare and intractable neurological diseases.
Japan 4884

Talk to a Data Expert

Have a question? We'll get back to you promptly.